RxDoctor Payments Data

Temitope Lawal, MD

Neurology · Greenville, NCNPI 1407376890

Payments from drug & device makers

$41,996in general payments, 2019–2025

Across 251 payments — averaging $167.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$21K
  • Boston Scientific$14K
  • Abbott$2K
  • Teva Pharmaceuticals USA, Inc.$842
  • Acadia Pharmaceuticals Inc$621
  • Neurocrine Biosciences, Inc.$457
  • plus $3K from 39 others

What the payments were for

  • Grants$30,00071%
  • Travel & lodging$5,44813%
  • Food & beverage$6,26115%
  • Education$2871%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,996 in reported general payments places this provider in the 80th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$207,506
Medicare patients
413
Services billed
13,959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate72$368,977
AustedoDeutetrabenazine17$208,541
Austedo XrDeutetrabenazine19$194,716
RytaryCarbidopa/Levodopa86$135,767
IngrezzaValbenazine Tosylate16$123,669
HorizantGabapentin Enacarbil15$28,538
Carbidopa-LevodopaCarbidopa/Levodopa691$17,419
Carbidopa-Levodopa ErCarbidopa/Levodopa252$8,149
Rasagiline Mesylate34$5,424
Primidone248$4,855
Gabapentin169$2,596
Glycopyrrolate65$2,557
Levetiracetam77$1,904
Memantine Hcl30$1,723
Baclofen106$1,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$842$403,25836 claims
Acadia Pharmaceuticals IncNuplazid$621$368,97772 claims
Amneal Pharmaceuticals LLCRytary$211$135,76786 claims
Neurocrine Biosciences, Inc.Ingrezza$457$123,66916 claims
Arbor Pharmaceuticals, Inc.Horizant$15$28,53815 claims
Upsher-smith Laboratories LLCTopiramate$17$47235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 566 neurology providers in North Carolina.

Other neurology in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →